Using natural exosome carriers to deliver chemotherapy directly to tumors
Exosomes as carriers of cancer therapeutics
This project uses tiny natural particles called exosomes to carry chemotherapy into lung tumors to try to improve treatment and reduce side effects for people with lung cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-11176165 on NIH RePORTER |
What this research studies
Researchers will load exosomes (tiny vesicles produced by cells) with iron‑oxide nanoparticles that are carrying chemotherapy drugs such as doxorubicin or cisplatin. The drug is attached to the nanoparticles with a pH‑sensitive linker so the medicine is released more inside acidic tumor areas than in normal tissues. The exosomes are further coated with a tumor‑targeting ligand to help direct them to lung cancer deposits. The iron‑oxide core also makes the particles visible by MRI so treatment delivery and tumor response can be tracked in lab and animal tests before any human use.
Who could benefit from this research
Good fit: People with lung cancer—especially those whose tumors do not respond well to current targeted or immune therapies—would be the most relevant group for this approach.
Not a fit: Patients with cancers other than lung cancer or those whose treatment plans do not use chemotherapy are unlikely to see direct benefit from this specific project.
Why it matters
Potential benefit: If successful, this could deliver chemo more precisely to tumors, increasing cancer cell kill while lowering side effects to healthy tissues.
How similar studies have performed: Related exosome‑ and nanoparticle‑based delivery methods have shown promising results in laboratory and animal studies, but they remain largely unproven in people so far.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Ramesh, Rajagopal — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Ramesh, Rajagopal
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.